Daraxonrasib doubled median overall survival to 13.2 months for metastatic pancreatic cancer patients failing first-line therapy, according to trial data published in the New England Journal of Medicine and reported by Sciences et Avenir.
Daraxonrasib Blocks RAS Mutations and Improves Quality of Life
- Universal inhibition: Daraxonrasib blocks multiple mutations in the RAS gene family rather than targeting just a single variant, effectively cutting off molecular growth signals in cancer cells.
- Oral administration: Unlike standard chemotherapy regimens that require intravenous hospital infusions, this medication is formulated as daily pills taken at home.
- Quality of life: Clinical evaluations indicate the treatment delayed pain progression to 9.2 months compared to 3.8 months under standard chemotherapy.
Daraxonrasib Doubles Median Survival in Phase III Trial
The phase III RASolute-302 clinical trial results received an extended ovation at the American Society of Clinical Oncology (ASCO) congress in Chicago. The trial demonstrated that daraxonrasib doubled median survival compared to the standard second-line chemotherapy benchmark of 6.7 months. Objective tumor reduction occurred in 31.6 percent of patients taking daraxonrasib, compared to 11.2 percent in the chemotherapy cohort, Sciences et Avenir reported.
Pascal Hammel, head of the digestive and medical oncology department at Paul-Brousse Hospital, noted initial skepticism given previous phase II trial failures.
“During my career, I’ve seen more than sixty phase II clinical trials with very promising results that ultimately failed in phase III, so when the American investigators contacted me in 2024 to participate in this phase III with daraxonrasib, I was very dubitative,” Hammel told Sciences et Avenir. He ultimately oversaw the French arm of the global study involving approximately 500 patients.
| Metric | Daraxonrasib Arm | Standard Chemotherapy |
|---|---|---|
| Median Overall Survival | 13.2 months | 6.7 months |
| Objective Response Rate | 31.6% | 11.2% |
| Delay Before Quality Degradation | 5.7 months | 2.6 months |
| Delay Before Pain Aggravation | 9.2 months | 3.8 months |
Cellular Mechanisms and Tumor Microenvironments
Pancreatic tumors create a dense, fibrous, poorly vascularized barrier that restricts systemic drugs from reaching cancer cells, according to Thierry Conroy, a digestive tumor specialist and honorary director of the Lorraine Cancer Institute.
Daraxonrasib acts as a pan-RAS inhibitor, targeting mutations in genes encoding RAS proteins. Normally, these proteins function as molecular switches regulating cell growth and division. Concurrently, neurobiologist Fanny Mann pointed out that the nervous system plays an active role, noting that sensitive nerve fibers infiltrate cancerous pancreatic lesions and signal the brain to promote disease progression.
Monitor Digestive Symptoms and Skin Toxicities During Treatment
Patients experiencing persistent digestive symptoms, unexplained weight loss, or abdominal pain should consult an oncologist immediately, as early-stage detection is necessary because only 10 to 15 percent of patients are operable at diagnosis.
While daraxonrasib extends survival, over 85 percent of patients treated with the drug experienced cutaneous eruptions, requiring dermatological management, dosage reductions, or discontinuation in 3 percent of cases. Patients with severe skin toxicities or those with unconfirmed non-KRAS mutated tumors require close clinical supervision during evaluation.
Regulatory Pathways and Future Research Directions
Following FDA authorization in the United States, the European Medicines Agency (EMA) initiated a phased review process in July to accelerate patient access. French experts anticipate early access approval by 2028. Ongoing research will test daraxonrasib in first-line settings, both as a monotherapy and combined with other molecules or chemotherapies, while exploring its efficacy against other RAS-mutated malignancies such as lung and colorectal cancers.
References
- Institut National du Cancer.
- American Society of Clinical Oncology (ASCO) Annual Meeting Proceedings
